N/A N=83 Remote Device Interrogation In The Emergency Department
Heart Disease · Cardiovascular Disease · Heart Failure
Primary: Time to Interrogation — 25; 210 Minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=302 Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin)
Advanced NET of GI Origin · Advanced NET of Lung Origin · Neuroendocrine Tumors
Primary: Probability of Participants Remaining Event-Free in Progression-Free Survival (PFS) Based on Central Radiology Assessment — 90.1; 74.6; 81.2; 49.1 Percent event-free…
Phase 4 N=40 Acetylcholinesterase Inhibitors to Improve Cognitive Function and Overall Rehabilitation After a Stroke
Cerebrovascular Accident
Primary: Physical Function (Measured by the FIM-motor) — 47.1; 49.4; 73.1; 87.4 units on a scale
Phase 2 N=22 Study for Pre-Surgical Weight Loss in Type II Diabetes Patients
Type 2 Diabetes · Obesity
Primary: % of Excess Weight Loss (EWL) — 37.7 % excess weight loss
Phase 3 N=607 Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.
Asthma · Wheezing
Primary: Progression to Clinically Significant Lower Respiratory Tract Symptoms — 35; 57 participants — p=0.04
Phase 4 N=83 Sitagliptin Therapy to Improve Outcomes After Islet Autotransplant
Pancreatitis · Diabetes
Primary: Insulin Independence — 42; 45 percentage of participants
Phase 4 N=241 Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Primary: Percentage of Participants Reporting Overall Flushing Events During the First 4 Weeks of Treatment, as Assessed by the Modified Global Flushing Severity Scale (MGFSS)…
Phase 3 N=942 A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HEC
Chemotherapy-induced Nausea and Vomiting
Primary: Delayed Phase Complete Response (CR) Rate — 64.7; 56.6 percentage of participants
Phase 3 N=1,428 APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Nausea and Vomiting · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1 — 160; 163; 156; 178 participants
Phase 3 N=213 Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Overall Treatment Preference by Subject's Preference Assessment (SPA) at Week 2 and Association With Baseline Characteristics — 49.5; 52.9; 46.2; 50.5 percentage of…
Early Phase 1 N=10 Investigation of the Glycemic Index of Ethiopian Honey
Hyperglycemia, Postprandial
Primary: Examine Effect of Monofloral Honey Types on Glycemic Index of Health Human Subjects — 54.73; 62.82; 60.31; 59.54 Index — p=<0.01
Phase 3 N=95 Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)
Borderline Personality Disorder
Primary: Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) — -1.22; -0.99; -0.75 units on a scale — p=.015
Phase 2 N=72 Alisertib in Treating Patients With Advanced or Metastatic Sarcoma
Myxofibrosarcoma · Recurrent Adult Soft Tissue Sarcoma · Recurrent Leiomyosarcoma
Primary: The Primary Endpoint for This Trial Was the Percent of Confirmed Tumor Responses. Confirmed Tumor Response to Treatment Was Defined as a Complete or Partial Response(Per…
Phase 2 N=558 Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Metastatic Colorectal Cancer (MK-0646-004)
Metastatic Colorectal Cancer
Primary: Overall Survival (OS) — 10.8; 11.6; 14.0 Months — p=0.06
N/A N=131 Melody® Transcatheter Pulmonary Valve Post-Approval Study
Dysfunctional Right Ventricular Outflow Tract (RVOT) Conduit
Primary: Acceptable TPV Hemodynamic Function at Six Months After Successful TPV Implantation — 96.7 percentage of patients